Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Clinical trials news


From To
Meta-analyses were supposed to end scientific debates. Often, they only cause more controversy

Although the basic rules of the meta-analysis are simple, researchers must make many choices along the way, allowing conscious or unconscious biases to creep in.

19 September 2018
FRESH program combines basic science with social benefits for women at risk of HIV

A program established by the Ragon Institute of MGH, MIT and Harvard is addressing the persistently elevated risk of HIV infection among young women in South Africa from two angles -- first, investigating biological factors that modulate infection risk and the early immunologic events following viral exposure, and second, alleviating the socioeconomic factors that limit opportunities for young women, the group at greatest risk in the region hit hardest by the HIV epidemic.

16 September 2018
Eurekalert Inf Dis
Half of Europe's clinical trials fail to report results despite EU rule

Almost half of all European-registered clinical trials - in which scientists test drug treatments, interventions or therapies in humans - have breached EU rules by failing to report results, according to an analysis published on Thursday.

13 September 2018
We Love the Jargon, We Hate the Jargon!

This blog post by Angelo Kaggwa-Katumba and Kay Marshall talks about the essential work of connecting journalists and researchers and how advocates are the linchpin.

20 July 2018
Will an HIV vaccine that protected two-thirds of monkeys do the same for humans?

The Lancet last Friday published the 52-week results of APPROACH, an HIV vaccine whose 28-week results, reported by last year, were sufficiently impressive for it to

13 July 2018
Gus Cairns
Superior AIDS-Kaposi’s Sarcoma Treatment Identified

A clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute comparing three chemotherapy regimens in combination with antiretroviral treatment (ART) for treatment of advanced AIDS-Kaposi’s sarcoma patients in Africa and South America has ended early. Interim data showed that participants who were treated with paclitaxel plus ART had better tumor outcomes than participants who received the other treatment regimens.

27 June 2018
National Institute of Allergies and Infectious Diseases (NIAID)
NHS England considers expanding PrEP trial - NAT comment

Deborah Gold, Chief Executive of NAT (National AIDS Trust) said: “This proposed trial expansion, from 10,000 to 13,000 participants, is essential and we urge NHS England to confirm the decision urgently. This expansion was first proposed by NAT as necessary to estimate accurately the likely long-term needs of a routinely commissioned PrEP programme and it’s great news that this is now on the table.

18 June 2018
National AIDS Trust
My PrEP story: Patrick (part 2)

In his second My PrEP Story blog Dr. Patrick Baxter talks about being on Gilead’s DISCOVER Trial. What’s the trial attempting to do? And why the lack of community consultation? And is he really using PrEP?

10 April 2018
Gay men seeking HIV-preventing PrEP drugs are being ‘turned away’ from sexual health clinics over trial capacity

More than two dozen sexual health clinics in England are now turning away gay men who are seeking to take HIV-preventing drugs, PinkNews has found.

21 March 2018
Pink News
Powerful new PrEP and treatment drug should be effective as a small weekly pill

MK-8591 or EFdA is a novel and exceptionally long-lasting and potent HIV drug, being developed by Merck. It is a nucleoside reverse transcriptase translocation inhibitor

12 March 2018
Gus Cairns
← First12345...22Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.